Follitropin-β administered by pen device has superior local tolerance compared with follitropin-α administered by conventional syringe

Reproductive BioMedicine Online

Volumn 3, Issue 3, 2001, Pages 185-189

  Craenmehr, E ^a   Bontje, P M ^a   Hoomans, E ^b   Voortman, G ^b   Mannaerts, B M J L ^b  

^a Kendle   (Netherlands)

^b NV ORGANON   (Netherlands)

Author keywords

injection; local tolerance; pain at injection site; pen device; recombinant FSH; self administration

Indexed keywords

RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; FEMALE; GENERAL MEDICAL DEVICE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE PAIN; NORMAL HUMAN; PEN INJECTOR; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN BRUISING; SKIN REDNESS; SWELLING; SYRINGE; VISUAL ANALOG SCALE;

EID: 85006132474     PISSN: 14726483     EISSN: 14726491     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)62033-0     Document Type: Article

References (13)

1. Albano, C, Smitz, J, Camus, M, et al. Pregnancy and birth in an in-vitro fertilization cycle after controlled ovarian stimulation in a woman with a history of allergic reaction human menopausal gonadotrophin. Human Reproduction 11 (1996), 1632–1634.
2. Brinsden, P, Akagbosu, F, Gibbons, LM, et al. A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization–embryo transfer. Fertility and Sterility 73 (2000), 114–116.
3. Kadiri, A, Chraibi, A, Marouan, F, et al. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Research and Clinical Practice 41 (1998), 15–23.
4. Mannaerts, BMJL, Rombout, F, Out, HJ, et al. Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy. Human Reproduction 11 (1996), 153–161.
5. Nancy, J, Bohannon, MD, Insulin delivery using pen devices–simple to use tools may help young and old alike. Postgraduate Medicine 106 (1999), 57–68.
6. Out, HJ, Mannaerts, BMJL, Driessen, SGAJ, et al. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle-stimulating hormone (Puregon vs Metrodin) in in-vitro fertilization. Human Reproduction 10 (1995), 2534–2540.
7. Out, HJ, Driessen, SGAJ, Mannaerts, BMJL, et al. Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins. Fertility and Sterility 68 (1997), 138–142.
8. Robertson, KE, Glazer, NB, Campbell, RK, The latest development in insulin injection devices. Diabetes Educator 26 (2000), 135–138.
9. Ruiz, PG, Balcke, P, Martinez, JM, et al. Tolerability of the Epoetin-Beta multidose formulation (Reco-Pen¯) in patients with renal anaemia. Clinical Drug Investigation 20 (2000), 151–158.
10. The European and Middle East Orgalutran Study Group, Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction 16 (2001), 644–651.
11. The European Orgalutran Study Group, Borm, G, Mannaerts, B, Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Human Reproduction 15 (2000), 1490–1498.
12. Verhoeff, A, Schmoutziguer, AP, Doesburg, WH, et al. A randoized study on the effects of intramuscular injections with urinary gonadotrophins (Humegon or Pergonal) on pain, local redness and fever in infertile women opting for in vitro fertilization. Human Reproduction 12 (1997), 1427–1429.
13. Voortman, G, van de Post, J, Schoemaker, RC, et al. Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon¯) by Pen-injector and syringe. Human Reproduction 14 (1999), 1698–1702.